Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire

Executive Summary

Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.

You may also be interested in...



Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen

Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab. 

Another Blow To Aduhelm As Biogen Withdraws EU Filing

Biogen has withdrawn its filing of the Alzheimer’s drug before the EMA could reject it for the second time, perhaps hoping it could return with better data.

Sandrock Joins Voyager As CEO To Advance New Gene Therapy Technology Into The Clinic

The former Biogen executive will succeed interim CEO Michael Higgins, who will continue as chairman.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel